{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:59:03Z","timestamp":1785153543332,"version":"3.55.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008196","name":"M\u00e9decins Sans Fronti\u00e8res","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bedaquiline resistance is increasing globally, threatening effectiveness of short regimens for rifampicin\/multidrug-resistant (RR\/MDR)-tuberculosis. Limited data exist describing the treatment and long-term outcomes of people with bedaquiline-resistant tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We did a retrospective cohort study of patients with bedaquiline-resistant tuberculosis in Karakalpakstan, Uzbekistan, from January 2017 until June 2025. Clinical and laboratory records were reviewed to describe treatment regimens, drug sensitivity profiles, and sputum results. We measured time to sustained sputum culture conversion (SCC), mortality, and the proportion of patients who had tuberculosis-free survival (alive, and had completed treatment or were in care, and had SCC) 18 months after bedaquiline resistance was detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 50 patients with bedaquiline-resistant tuberculosis who received treatment, the median age was 41 years (IQR: 27\u201352), 64% (32\/50) were male, 69% (34\/49) had fluoroquinolone resistance, and 32% (16\/50) had not previously received bedaquiline. The median treatment duration was 18.8 months (IQR: 9.0\u201322.4), with bedaquiline prescribed for 84% for a median 5.6 months (IQR: 2.2\u201312.9), imipenem for 66% for a median 8.1 months (IQR: 4.5\u201311.3), and amikacin for 50% for a median 7.9 months (IQR: 4.4\u201311.1). The median time to SCC was 5.9 months (IQR: 2.1\u201315.9) and the probabilities of survival to 18 months and 5 years were 79.7% (95% CI: 69.2\u201391.8) and 63.4% (95% CI: 48.8\u201382.4). Of 48 patients who had an assessable 18-month outcome, 60.4% (29\/48) had tuberculosis-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Management of bedaquiline-resistant tuberculosis in Uzbekistan required prolonged antituberculosis therapy, often with injectables, resulting in delayed culture conversion and poor long-term health outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag405","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:38:38Z","timestamp":1784533118000},"source":"Crossref","is-referenced-by-count":0,"title":["Characteristics, Treatment Strategies, and Long-term Health Outcomes of People With Bedaquiline-resistant Tuberculosis in Karakalpakstan, Uzbekistan\u2014A Retrospective Cohort Study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3033-2367","authenticated-orcid":false,"given":"Matthew J","family":"Saunders","sequence":"first","affiliation":[{"name":"Manson Unit, M\u00e9decins Sans Fronti\u00e8res , London ,","place":["UK"]},{"name":"Institute for Infection and Immunity, City St George\u2019s, University of London , London ,","place":["UK"]},{"name":"Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterine","family":"Garsevanidze","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sholpan","family":"Allamuratova","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0161-7702","authenticated-orcid":false,"given":"Viktorya","family":"Cholakyans","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3856-7407","authenticated-orcid":false,"given":"Jaishankar","family":"Sharma","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azamat","family":"Ismailov","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gomez","sequence":"additional","affiliation":[{"name":"Public Health Department, M\u00e9decins Sans Fronti\u00e8res , Amsterdam ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L","family":"Rekart","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvati","family":"Nair","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2527-592X","authenticated-orcid":false,"given":"Soe","family":"Moe","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Tigay","sequence":"additional","affiliation":[{"name":"Republican Center of Tuberculosis and Pulmonology , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargiza","family":"Parpieva","sequence":"additional","affiliation":[{"name":"Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khasan","family":"Safaev","sequence":"additional","affiliation":[{"name":"Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Gomez-Restrepo","sequence":"additional","affiliation":[{"name":"Medical Department, M\u00e9decins Sans Fronti\u00e8res , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2186-8530","authenticated-orcid":false,"given":"Norman","family":"Sitali","sequence":"additional","affiliation":[{"name":"Public Health Department, M\u00e9decins Sans Fronti\u00e8res , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Manson Unit, M\u00e9decins Sans Fronti\u00e8res , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-7813","authenticated-orcid":false,"given":"Animesh","family":"Sinha","sequence":"additional","affiliation":[{"name":"Manson Unit, M\u00e9decins Sans Fronti\u00e8res , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026072707020206000_ofag405-B1","doi-asserted-by":"crossref","DOI":"10.54394\/CJQU6666","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024"},{"key":"2026072707020206000_ofag405-B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026072707020206000_ofag405-B3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026072707020206000_ofag405-B4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1056\/NEJMc2404644","article-title":"Transmission as a key driver of resistance to the new tuberculosis drugs","volume":"392","author":"Goig","year":"2025","journal-title":"N Engl J Med"},{"key":"2026072707020206000_ofag405-B5","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1016\/S2214-109X(23)00369-8","article-title":"Costs incurred by people receiving tuberculosis treatment in low-income and middle-income countries: a meta-regression analysis","volume":"11","author":"Portnoy","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2026072707020206000_ofag405-B6","doi-asserted-by":"crossref","first-page":"100909","DOI":"10.1016\/S2666-5247(24)00149-6","article-title":"Bedaquiline: what might the future hold?","volume":"5","author":"Shaw","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026072707020206000_ofag405-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2229-516X.112228","article-title":"Bedaquiline: first FDA-approved tuberculosis drug in 40 years","volume":"3","author":"Mahajan","year":"2013","journal-title":"Int J Appl Basic Med Res"},{"key":"2026072707020206000_ofag405-B8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang'wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026072707020206000_ofag405-B9","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2026072707020206000_ofag405-B10","volume-title":"WHO Consolidated guidelines on tuberculosis. Module 4: treatment and care","author":"World Health Organization","year":"2022"},{"key":"2026072707020206000_ofag405-B11","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026072707020206000_ofag405-B12","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.06126-11","article-title":"Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026072707020206000_ofag405-B13","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2666-5247(20)30031-8","article-title":"Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in Southern Africa: a phenotypic and phylogenetic analysis","volume":"1","author":"Nimmo","year":"2020","journal-title":"Lancet Microbe"},{"key":"2026072707020206000_ofag405-B14","doi-asserted-by":"crossref","first-page":"2300639","DOI":"10.1183\/13993003.00639-2023","article-title":"Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"62","author":"Perumal","year":"2023","journal-title":"Eur Respir J"},{"key":"2026072707020206000_ofag405-B15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1473-3099(23)00498-X","article-title":"Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB\/RIF in Mozambique: a retrospective observational study","volume":"24","author":"Barilar","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026072707020206000_ofag405-B16","volume-title":"WHO Consolidated guidelines on tuberculosis. Module 4: treatment and care","author":"World Health Organization","year":"2025"},{"key":"2026072707020206000_ofag405-B17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1473-3099(25)00218-X","article-title":"Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study","volume":"25","author":"Mdlenyani","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026072707020206000_ofag405-B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5588\/ijtldopen.24.0351","article-title":"Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan","volume":"1","author":"Moe","year":"2024","journal-title":"IJTLD Open"},{"key":"2026072707020206000_ofag405-B19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5588\/ijtld.22.0536","article-title":"Primary bedaquiline resistance in Karakalpakstan, Uzbekistan","volume":"27","author":"Moe","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026072707020206000_ofag405-B20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.5588\/ijtld.21.0631","article-title":"Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan","volume":"26","author":"Nair","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026072707020206000_ofag405-B21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/cid\/ciaf035","article-title":"The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant Tuberculosis in non-trial settings-a prospective cohort study in Belarus and Uzbekistan","volume":"81","author":"Sinha","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026072707020206000_ofag405-B22","doi-asserted-by":"crossref","first-page":"e1126","DOI":"10.1371\/journal.pone.0001126","article-title":"Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures","volume":"2","author":"Cox","year":"2007","journal-title":"PLoS One"},{"key":"2026072707020206000_ofag405-B23","volume-title":"Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2018"},{"key":"2026072707020206000_ofag405-B24","volume-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance","author":"World Health Organization","year":"2023","edition":"2nd ed"},{"key":"2026072707020206000_ofag405-B25","doi-asserted-by":"crossref","first-page":"1900391","DOI":"10.1183\/13993003.00391-2019","article-title":"Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe","volume":"53","author":"Migliori","year":"2019","journal-title":"Eur Respir J"},{"key":"2026072707020206000_ofag405-B26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jinf.2023.01.039","article-title":"Pretomanid-resistant tuberculosis","volume":"86","author":"Koehler","year":"2023","journal-title":"J Infect"},{"key":"2026072707020206000_ofag405-B27","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline resistance: its emergence, mechanism, and prevention","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026072707020206000_ofag405-B28","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/S2666-5247(23)00317-8","article-title":"Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis","volume":"5","author":"Nimmo","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026072707020206000_ofag405-B29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1473-3099(24)00586-3","article-title":"Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows","volume":"25","author":"Colman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026072707020206000_ofag405-B30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(24)00602-9","article-title":"The promise and the reality of targeted next-generation sequencing for drug-resistant tuberculosis detection","volume":"25","author":"Marais","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026072707020206000_ofag405-B31","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1473-3099(24)00263-9","article-title":"Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"24","author":"Schwab","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026072707020206000_ofag405-B32","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa055524","article-title":"Microscopic-observation drug-susceptibility assay for the diagnosis of TB","volume":"355","author":"Moore","year":"2006","journal-title":"N Engl J Med"},{"key":"2026072707020206000_ofag405-B33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2471\/BLT.13.124800","article-title":"Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis","volume":"92","author":"MacPherson","year":"2014","journal-title":"Bull World Health Organ"},{"key":"2026072707020206000_ofag405-B34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ijms17030373","article-title":"Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review","volume":"17","author":"Sotgiu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2026072707020206000_ofag405-B35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7196\/SAMJ.7263","article-title":"Clinical access to bedaquiline programme for the treatment of drug-resistant tuberculosis","volume":"104","author":"Conradie","year":"2014","journal-title":"S Afr Med J"},{"key":"2026072707020206000_ofag405-B36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag405\/69526541\/ofag405.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag405\/69526541\/ofag405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag405\/69526541\/ofag405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:02:11Z","timestamp":1785150131000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag405\/8737872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag405","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"ofag405"}}